Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH; TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, has priced its underwritten public offering of 22,300,000 common shares at US $6.75 per share for gross offering proceeds of approximately US $150.5 million.
The offering is expected to close on or about March 20, 2017, subject to the satisfaction of customary closing conditions.
Leerink Partners LLC and Cantor Fitzgerald & Co. are acting as joint book-running managers.
Aurinia Pharmaceuticals intends to use the net proceeds for research and development activities, including Phase 3 clinical trial activities for lupus nephritis, and working capital purposes.
In December 2016, Aurinia Pharmaceuticals completed an offering of 12,777,775 units at US $2.25 per unit for gross proceeds of US $28.75 million.
Aurinia Pharmaceuticals’ major investors include ILJIN Group and venBio Global Strategic Fund. ILJIN Group, the largest shareholder, participated in the last offerin, subscribing for 1,333,333 units for US $3 million.
photo credit: Aurinia Pharmaceuticals
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Nudge Rewards secures US $9.3M Series B led by Jump Capital - August 16, 2019
- ONCAP invests in International Language Academy - August 16, 2019
- Novacap, CDPQ backed Nuvei closes US $889M acquisition of SafeCharge - August 14, 2019